Protein Therapeutics Market to grow with a CAGR of 6.80%

Increasing healthcare infrastructure and a supportive regulatory environment are the major drivers for the Global Protein Therapeutics Market.

According to TechSci Research report, “Global Protein Therapeutics Market Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028”, Global Protein Therapeutics Market has valued at USD 271.26 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 6.80% through 2028. This can be due to collaborations and partnerships among leading companies with a diverse approach to merge the expertise of individual companies and to strengthen their position in the market.

Global health crises, such as pandemics and outbreaks of infectious diseases, can drive the demand for protein therapeutics. Protein therapeutics are essential in the development of vaccines. Vaccines typically contain viral or bacterial proteins, or protein fragments, that stimulate the immune system to produce an immune response. During a global health crisis like a pandemic, the rapid development and distribution of vaccines are crucial to prevent the spread of the disease. Monoclonal antibodies, a type of protein therapeutic, have been used in the treatment of infectious diseases. For example, monoclonal antibodies have been employed in the treatment of COVID-19 to neutralize the virus and reduce disease severity in infected individuals. Some protein therapeutics, such as interferons and antiviral antibodies, are used to combat viral infections directly by interfering with viral replication and spread. Inflammatory responses can contribute to the severity of certain infectious diseases. Protein therapeutics, such as cytokines and immune modulators, can help regulate and modulate the immune response during a crisis, potentially reducing tissue damage and improving patient outcomes.

Protein treatments provide the body with proteins in precise amounts (depending on the patient's needs) to cure a variety of illnesses, including diabetes, anaemia, chronic renal failure, and structural repair. Therapeutic proteins are strong, quick-acting medications that have been shown to be particularly successful in treating a range of disorders. Opportunities to enhance protein treatments will persist as our knowledge of the molecular causes of disease expands.

In June 2019, the clinical-stage gene therapy business Nightstar Therapeutics, which specializes in adeno-associated virus (AAV) therapies for hereditary retinal illnesses, has been acquired by Biogen, according to a company announcement. Due to the purchase, Biogen currently possesses two mid- to late-stage clinical assets as well as an ophthalmology-related preclinical program. The main asset of NST is NSR-REP1, which is being developed by the company to treat choroideremia (CHM), a blinding, X-linked genetic retinal condition that is uncommon and degenerative. The Rab escort protein-1 (REP-1) is encoded by the CHM gene, a loss of function in this gene results in CHM, which mostly affects men. Patients with CHM initially have poor night vision, and with time, progressive vision loss eventually results in total blindness.

Browse over XX market data Figures and spread through 110 Pages and an in-depth TOC on "Protein Therapeutics Market”

Rising development costs are a significant challenge in the global protein therapeutics market. The development of protein-based therapeutics, like monoclonal antibodies, enzymes, and vaccines, involves substantial financial investments and resource allocation. Protein therapeutics require extensive research and development efforts, from the initial discovery and validation of potential targets to preclinical and clinical testing. The complexity of biologic drug development often results in longer timelines and higher costs compared to small-molecule drugs. Protein therapeutics typically undergo multiple phases of clinical trials, including Phase I, Phase II, and Phase III trials. These trials involve large patient populations, extensive data collection, and monitoring, all of which contribute to rising costs.

Global Protein Therapeutics Market segmentation is based on Protein Function, Product Type, Region and Company

Based on Product Type, Global Protein Therapeutics Market is segmented into Blood Clotting Factor, Erythropoietin, Follicle Stimulating Hormone, G-CSF, Insulin, Interferons, Monoclonal Antibodies. Follicle-Stimulating Hormone (FSH) is a crucial hormone that plays a significant role in the reproductive system, particularly in the functioning of the ovaries and testes. FSH is a glycoprotein hormone, which means it consists of a protein component and a carbohydrate component. FSH is produced and released by the anterior pituitary gland, a small gland located at the base of the brain. It is synthesized and secreted in response to gonadotropin-releasing hormone (GnRH) produced by the hypothalamus. In females, FSH plays a crucial role in the development and maturation of ovarian follicles. Each ovarian follicle contains an immature egg (oocyte) and surrounding cells. FSH stimulates the growth and development of these follicles during the menstrual cycle. In males, FSH is essential for spermatogenesis, the process by which sperm cells are produced in the testes. FSH acts on Sertoli cells within the testes, promoting their growth and function. Sertoli cells, in turn, support and nourish developing sperm cells.

Based on Region, North America dominated the Global Protein Therapeutics Market. North America has access to substantial capital markets, including venture capital, private equity, and public markets. This financial support enables biotechnology startups and established companies to fund their research and development efforts. The North American market for healthcare products is one of the largest and most diverse in the world. This market size encourages pharmaceutical companies to prioritize North America for product launches and market expansion. The region boasts a high concentration of key opinion leaders in various medical fields. These experts influence clinical practice and drug adoption, making it important for pharmaceutical companies to establish a presence in North America. North America has well-established intellectual property protection laws, which encourage innovation by ensuring that companies can protect their investments in research and development.

Asia-pacific region to fastest growth in the Global Protein Therapeutics Market. Many countries in the Asia-Pacific region are experiencing increased healthcare spending due to rising incomes, expanding middle-class populations, and government initiatives to improve healthcare access. This increased funding has boosted the demand for advanced therapies, including protein therapeutics. Like many parts of the world, the Asia-Pacific region is also witnessing an aging population. With an aging demographic comes a higher prevalence of age-related diseases and chronic conditions, which often require protein-based therapies for treatment and management. The region is facing a growing burden of chronic diseases, such as cancer, diabetes, cardiovascular diseases, and autoimmune disorders. These conditions often necessitate the use of protein therapeutics, including monoclonal antibodies and cytokines, for effective treatment. Cancer rates are on the rise in the Asia-Pacific region. As a result, the demand for cancer immunotherapies, which often include protein-based monoclonal antibodies and targeted therapies, has increased significantly.

Some of the major companies operating in the Global Protein Therapeutics Market include:

Amgen Inc.
Eli Lilly and Company.
F. Hoffmann-La Roche Ltd.
Johnson & Johnson Services, Inc
Merck KGaA
Pfizer Inc
AstraZeneca Plc.
Teva Pharmaceutical Industries Ltd
Bristol-Myers Squibb Company
AbbVie Inc.

Download Free Sample Report

Customers can also request 10% free customization on this report

“Certain areas, particularly in North America, are projected to exert significant demand for Protein Therapeutics. The growth in the competitive landscape and the presence of well-established companies in the market, committed to enhance the overall wellbeing of people each year, are expected to contribute to a remarkable growth of the Global Protein Therapeutics Market in the forecast period," said Mr. Karan Chechi, Research Director with TechSci Research, a research-based Global management consulting firm.

Protein Therapeutics Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Protein Function (Enzymatic & Regulatory, Protein Diagnostics, Vaccines), by Product Type (Blood Clotting Factor, Erythropoietin, Follicle Stimulating Hormone, G-CSF, Insulin, Interferons, Monoclonal Antibodies), by region, and Competition evaluated the future growth potential of Global Protein Therapeutics Market and provides statistics & information on market size, structure, and future market growth. The report intends to provide innovative market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Protein Therapeutics Market.

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York 10017

Tel: +1-646-360-1656

Email: [email protected]

Website: www.techsciresearch.com